CARDIOVASCULAR

Combining the expertise of proven investment professionals and world-renowned clinicians
 
Steven Ajluni, MD, FACC

BioStar III

Steven Ajluni, MD, is a physician leader at William Beaumont Hospital and CEO of the Michigan Heart Group, Heartpointe Cardiology. He has been a practicing interventional cardiologist for 25 years and is a Clinical Assistant Professor at Oakland University William Beaumont School of Medicine. Dr. Ajluni has been an active investor in multiple medical device venture capital funds and startup business ventures and has served successfully on the Board of Directors of Epsilon Imaging, a pioneering cardiovascular diagnostic imaging company.

David Kandzari, MD

BioStar III

David Kandzari, MD, is the Director of Interventional Cardiology and Chief Scientific Officer at the Piedmont Heart Institute in Atlanta, Georgia. Dr. Kandzari has held appointments as the Chief Medical Officer for the Cordis Corporation (Johnson & Johnson) and as a Medical Officer for the US Food and Drug Administrator (FDA) As a regulatory expert, Dr. Kandzari is a Committee Member for the FDA’s Circulatory Systems Devices Panel. He is a renowned clinical trial investigator and has held national and international leadership roles in clinical trials surrounding cardiovascular disease. Dr. Kandzari is a graduate of Duke University, where he also completed his cardiology fellowship. Dr. Kandzari completed his residency and internship at the John Hopkins University School of Medicine.

Vivek Y. Reddy, MD

BioStar III

Vivek Y. Reddy, MD, is the Director of Electrophysiology Laboratories at The Mount Sinai Medical Center. Dr. Reddy’s research focuses on using catheter ablation to treat complex cardiac arrhythmias such as atrial fibrillation, ventricular tachycardia, and resynchronization therapies that are used to treat congestive heart failure. He has published numerous articles, most famously a seminal multicenter clinical trial on ventricular tachycardia ablation. Known as SMASH-VT (Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia), the study examined the use of prophylactic catheter ablation to prevent shocks in patients receiving defibrillators. The findings from SMASH-VT were published in the New England Journal of Medicine. After earning his medical degree from the University of Michigan in Ann Arbor, Dr. Reddy completed a residency in internal medicine at Yale University Hospital in New Haven, Connecticut. He then completed a clinical cardiology fellowship at the University of Chicago Hospitals in Illinois and also a clinical and research cardiac electrophysiology fellowship at Massachusetts General Hospital in Boston. He has received numerous honors, including the Center for Minimally Invasive Therapy Fellowship and the Howard Hughes Medical Institute Scholarship.
 

Robert Schwartz, MD, FACC, FAHA, FSCCT

BioStar III

Robert Schwartz, MD, is a practicing Senior Consulting Cardiologist at the Minneapolis Heart Institute and is Director of Advanced Imaging Research. He is world renowned in medical devices, medical technology, and Cardiovascular Biology. In addition to Cardiology he has extensive Graduate training as an Electrical and Biomedical Engineer and is named on more 70 patents and 400 scientific publications. He is Founder/Co-Founder of several successful Medical startup ventures including the BioStar portfolio companies Atritech (acquired by Boston Scientific Corporation) and Autonomix Medical, and he serves on multiple consulting and technical Advisory Boards.

Frank Shannon, MD, FACS

BioStar II, BioStar III

Frank Shannon, MD, is a cardiovascular surgeon with William Beaumont Hospital in Royal Oak, Michigan. Dr. Shannon has authored numerous publications in cardiovascular and general surgery, and is a reviewer for the Annals of Thoracic Surgery. Dr. Shannon is a well-known surgical valve design innovator, with particular expertise in mitral and tricuspid valve systems, percutaneous/minimally accessible mitral annular remodeling devices, aortic valves, and minimally invasive devices used in atrial ablation procedures. Dr. Shannon sits on the scientific advisory board of Micardia, a BioStar Ventures portfolio company, and is a consultant to Medtronic, Datascope, and Pequot Capital Management.
 

Gregg W. Stone, MD, FACC, FACP

BioStar II, BioStar III

Gregg Stone, MD, is an internationally recognized cardiologist who has led more than 40 trials and has served as the national or international principle investigator for more than 25 multicenter randomized clinical trials. Dr. Stone practices interventional cardiology at Lenox Hill Hospital in New York and has performed more than 5,000 angioplasty and stent procedures. Dr. Stone has particular expertise in drug-eluting stents, vulnerable plaque, acute coronary syndromes, myocardial infarction, antithrombotic and antiplatelet agents, contrast nephropathy, transcatheter valve therapies and new device development. Dr. Stone directs the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, the world’s largest symposium devoted to interventional cardiology and vascular medicine. Dr. Stone is triple board certified in Interventional Cardiology, Cardiovascular Disease and Internal Medicine. He is Professor of Medicine at Columbia University Medical Center and the immediate past chairman of the Cardiovascular Research Foundation in New York.

 

Steve Yakubov, MD, FACC

BioStar II, BioStar III

Steve Yakubov, MD, is an interventional cardiologist and the Medical Director of the Mid West Cardiology Research Foundation in Columbus, Ohio. Dr. Yakubov has been involved with more than 75 active clinical trials involving interventional cardiology, peripheral vascular medicine and electrophysiology. Dr. Yakubov runs the third largest clinical trial site in the United States. He is widely published and sits on the scientific advisory boards of several start-up companies including RTI, a BioStar Ventures portfolio company. In February 2007, Dr. Yakubov was named the Number One cardiologist in central Ohio, according to an exclusive survey of 5,000 doctors in seven central Ohio counties.